MARATTO

article · Microbes and Infectious Diseases /Microbes and Infectious Diseases

Interferon-Induced Transmembrane Protein 3 (IFITM3) gene Polymorphisms in COVID-19 patients in Assiut University Hospitals

2024Open accessAssiut University

Abstract

Background and aims: Interferon-induced transmembrane protein 3 (IFITM3) plays an important antiviral role in the adaptive and innate immune response, it prevents hemifusion of the viral membrane and host cellular membrane in a broad spectrum of enveloped viruses, e.g. influenza A, Ebola, Marburg or SARS-CoV. This study aimed to evaluate correlation of IFITM3 gene polymorphisms (rs12252) and infection susceptibility, severity and mortality rate of COVID-19 patients. Patients and Methods: The IFITM3 SNP (rs12252) polymorphism was genotyped by (RT-PCR) in 100 SARS-CoV-2-negative controls and 100 SARS-CoV-2- positive, who admitted to Chest, Assiut University and other quarantine Hospitals respectively in Assiut city, Egypt. Results: The minor allele frequency (rs12252 (G)) were significantly more frequent in the patients compared to controls after age and sex matching (P-Value = 0.011, OR (95% CI) =2.44 (1.20-4.97). This allele (G) was significantly more common among patients who ICU admitted than non-ICU admitted (P-Value = 0.001, OR (95% CI) =3.78 (1.64-8.75)). Also, was significantly more frequent in dead patients than cured patients (P-Value = 0.005, OR (95% CI) =3.33 (1.37-8.10)). Conclusion: The present study has shown significant association between G (the mutant type) allele variant of IFITM3 rs12252 and COVID-19 infection susceptibility and disease severity and mortality. Keywords: SARS-CoV-2, SNP, Genotyping, rs12252, RT-PCR.

Research topics

  • Viral Infections and Vectors
  • COVID-19 Clinical Research Studies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/mid.2024.258008.1732

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.